Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
作者： Ming Hui Chen
DOI: 10.1007/S11886-009-0025-9
关键词: Medicine 、 Targeted therapy 、 Monoclonal antibody 、 Cardiotoxicity 、 Sunitinib 、 Heart failure 、 Trastuzumab 、 Pharmacology 、 Myocardial infarction 、 Tyrosine kinase
摘要: Increasing use of targeted anticancer agents that inhibit tyrosine kinase signaling (monoclonal antibodies or inhibitors) has dramatically improved the survival patients with malignancies. However, cardiotoxicity, including heart failure, left ventricular dysfunction, hypertension, myocardial infarction, and thromboembolism, occurred. Importantly, these cardiotoxicities are at least partially reversible responsive to medical management. Early recognition cardiovascular side effects is vital allow long-term, continuous therapy life-prolonging agents. This article reviews potential frequently used inhibitors activity (eg, trastuzumab, sunitinib) discusses diagnosis management cardiotoxicity associated therapy.
springer.com
sci-hub.se 参考文章(57)
Paul Richardson, Optimizing bortezomib treatment in patients with relapsed multiple myeloma. Clinical advances in hematology & oncology. ,vol. 4, pp. 4- 12 ,(2006)
Sharon Ann Hunt, None, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. ,vol. 46, pp. 1116- 1143 ,(2005) , 10.1016/J.JACC.2005.08.022
Edith A Perez, Edward H Romond, Dennis J Slamon, Advances in adjuvant therapy for breast cancer. Clinical advances in hematology & oncology. ,vol. 4, pp. 1- 10 ,(2006)
M.L. Telli, R.M. Witteles, G.A. Fisher, S. Srinivas, Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Annals of Oncology. ,vol. 19, pp. 1613- 1618 ,(2008) , 10.1093/ANNONC/MDN168
Heikki Joensuu, Sunitinib for imatinib-resistant GIST The Lancet. ,vol. 368, pp. 1303- 1304 ,(2006) , 10.1016/S0140-6736(06)69489-0
Daniel J. Lenihan, Tyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork? Journal of Clinical Oncology. ,vol. 26, pp. 5154- 5155 ,(2008) , 10.1200/JCO.2008.18.5439
Edith A. Perez, Maria Koehler, Julie Byrne, Alaknanda J. Preston, Erica Rappold, Michael S. Ewer, Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials Mayo Clinic Proceedings. ,vol. 83, pp. 679- 686 ,(2008) , 10.4065/83.6.679
Thomas Force, Daniela S. Krause, Richard A. Van Etten, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer. ,vol. 7, pp. 332- 344 ,(2007) , 10.1038/NRC2106
Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb, Anthony Rosenzweig, Robert N Salomon, Richard A Van Etten, Joseph Alroy, Jean-Bernard Durand, Thomas Force, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine. ,vol. 12, pp. 908- 916 ,(2006) , 10.1038/NM1446
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655